Oncolytics Biotech Inc. (ONCY)
| Market Cap | 145.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.51M |
| Shares Out | 54.67M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $2.65 |
| Previous Close | $2.65 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 2.68 |
| Day's Range | 2.63 - 2.73 |
| Day's Volume | 435,089 |
| 52-Week Range | 1.52 - 4.83 |
SAN DIEGO and CALGARY, AB, May 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting of Shareholders held on Fri...
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize wi...
Management will also provide its annual corporate update after the conclusion of the meeting SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS...
SAN DIEGO and CALGARY, AB, April 29, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial ...
Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade ther...
- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classificati...
SAN DIEGO and CALGARY, AB, April 12, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multi...
SAN DIEGO and CALGARY, Alberta, April 8, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer...
SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, ...
Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
SAN DIEGO and CALGARY, AB, March 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportu...
SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /PRNewswire/ ---- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus,...
- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On t...
SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 20...
iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines ...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings ...
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended Septem...
- Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET SAN DIEGO and CALGARY, AB, Nov. 6, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today...
SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc.
SAN DIEGO, Calif. and CALGARY, AB, Aug.
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TNBC) study ...
SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vir...
SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canacc...
SAN DIEGO and CALGARY, Alberta, May 29, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...
SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...
SAN DIEGO and CALGARY, Alberta, May 14, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...
Oncolytics Biotech's (ONCY) CEO Matt Coffey on Q4 2019 Results - Earnings Call Transcript
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.
Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020
As of late, it has definitely been a great time to be an investor in Oncolytics.
Oncolytics Biotech Inc. (ONCY) CEO Dr.
About ONCY
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-n... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 1999 |
| Stock Exchange NASDAQ | Ticker Symbol ONCY |